NIH | National Cancer Institute | NCI Wiki  

WIKI MAINTENANCE NOTICE

Please be advised that NCI Wiki will be undergoing maintenance Monday, July 22nd between 1700 ET and 1800 ET and will be unavailable during this period.
Please ensure all work is saved before said time.

If you have any questions or concerns, please contact the CBIIT Atlassian Management Team.

Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

...

Goals

  • Discuss updates to ICDC and define emerging strategies and priorities

...

  • Request for Information (RFI) has been issued
  • RFI has been promoted through the following channels
  • 2 focus groups met Ideas from the ICDC brainstorming sessions final.docx
    ItemWhoTalking Points
    DGAB Updates

    ICDC Studies in the Queue

    • UBC03
      • Approved by SAC on 8/13/22
      • "Transcriptomic analyses of early stage bladder cancer in Scottish Terriers detected through screening"
      • Purdue University
      • 19 cases
      • Status: Submitters generating template-based data loading files
    • OSA02
      • Approved by SAC on 9/21/22
      • "Immune Pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma"
      • Colorado State University
      • 108 cases
      • Status: Submitters generating template-based data loading files
    • ORGANOIDS01
      • Approved by SAC on12/5/22
      • “Characterization of healthy and diseased canine tissues and organoids"
      • Iowa State University
      • Status: Submitters generating template-based data loading files
    • UBCO4
      • Approved by SAC on 12/22/22
      • "Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation"
      • North Carolina State University
      • 36 cases
      • Status: Onboarding kick-off call on 1/5/23
    • PRECINCT01 
      • Approved by SAC on 6/28/22
      • "Inhaled IL-15 Immunotherapy for Treatment of Lung Metastases"
      • UC Davis
      • 21 cases
      • Status: Data not yet available
    • PRECINCT02
      • Approved by SAC on 12/8/22
      • "Novel treatments for Diffuse large B cell lymphoma (DLBCL) in dogs"
      • Tufts University
      • 47 cases
      • Status: Data not yet available
    • PANCAN01
      • Approved by SAC on 11/8/21
      • "Canine tumor mutational burden is correleated with TP53 mutation across tumor types and breeds"
      • University of Georgia
      • 684 cases
      • Status: Submitters generating template-based data loading files
    • UMCVM
      • Approved by SAC on 4/19/21
      • "Comparative analysis of genome-wide DNA methylation identifies patterns that associate with conserved transcriptional programs in osteosarcoma"
      • University of Minnesota
      • 44 cases
      • Status: On hold until FTE is designated
    BPSC Updates
    • 2022 BPSC Review Article
      • Jeff Trent reached out relevant journal contacts
      • Feedback received will require us to emphasize the connection between dogs and humans and the value of canine as a comparative model
      • The paper has a genomic focus, however the comparative trials that exist are drug focused
      • Ideally we can site papers and studies that highlight relevant mechanisms with a genomic facet
      • No additional edits are allowed at this time
      • Authors are entering applicable PubMed central IDs
      • Cheryl London is completing references in EndNote
    Upcoming Steering Committee Meeting
    • Tuesday February 28, 2023
    • Proposed Agenda:

      Updates – Debbie

      Data Governance Advisory Board (DGAB) - Warren 

          • Genomic Data Guidelines – Elaine
          • Study Nominations/Data Submissions - Gina

      Best Practices Subcommittee (BPS) – Jeff 

          • White Paper/Publication – Jeff 
          • Genomics Working Group - Elaine, Debbie 
          • Imaging Working Group - Amy, Paula

      Presentations, New Collaborations, Opportunities - all

      Possible expansion of the Steering Committee

      Other Topics – all

      Administrative Topics – Ralph 

    ICDC Next Phase Planning

    ...

    Minutes (Not Verbatim)

    TH - Look at drug responses and the tumor itself to determine if there is a biomarker based on genomic expression. In the Intro of the BPSC paper, we could give examples of things that can be done based upon existing drug trial studies. 

    AL - In general, there is such a scarcity of credentialed biology in tumor progression. Drug mechanisms can be highlighted with an imaging reporter. 

    DK - Pre and post biopsies were attempted in Vemurafinib trial

    AL - Until we have DBs to refer to and a more stable reference genome it is difficult to make progress.


    Previous ICDC Use Cases from Steering Committee

    ...